At the news
? BULLISHIMPACT 7/10 425 filed Jul 22, 2026 at 09:00 ET
Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal, expanding its cell therapy capabilities. The company also reported preliminary Q2 2026 revenue growth of ~12% (13% organic) and expects strong margin expansion. The transaction is expected to close in Q4 2026 and be accretive to adjusted EPS by at least $0.05 in year one.
- Acquisition of BioLife Solutions for $11.25 cash + 0.1442 RGEN shares per BLFS share, total enterprise value ~$1.5B
- Implied premium of 24% to 90-day VWAP
- Expected to close in Q4 2026, subject to regulatory and BioLife shareholder approvals
- Repligen expects at least $20M synergies in year one, $30M in year two
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access